Cited by 236Adrenal and Paraganglionic TumorsRenal cell carcinoma treatmentAdrenal Hormones and Disorders

The DOI matches its Crossref record; 50 of the 54 references it cites were found in a registry or an index.

Prognostic Parameters of Metastatic Adrenocortical Carcinoma

Assié, Guillaume, Antoni, Guillemette, Tissier, Frédérique, Caillou, Bernard, Abiven, Gwenaelle, Gicquel, Christine, Leboulleux, Sophie, Travagli, Jean-Paul, Dromain, Clarisse, Bertagna, Xavier, Bertherat, Jérôme, Schlumberger, Martin, Baudin, Eric·2007·The Journal of Clinical Endocrinology & Metabolism

DOI 10.1210/jc.2006-0706

Open this paper in CoChat — free account

Abstract

CONTEXT: Prognostic parameters of metastatic adrenocortical carcinoma (ACC) are poorly characterized. OBJECTIVE: The objective of the study was to describe the clinical presentation of metastatic ACC and determine prognostic factors for survival. DESIGN: This was a retrospective cohort study (1988-2004). SETTING: The study was conducted in an institutional practice. PATIENTS: Participants included 124 consecutive patients with metastatic ACC, 70 from Gustave-Roussy Institute (main cohort) and 54 patients from the Cochin Hospital (validation cohort). Clinical data concerning all patients, histopathologic slides of primary tumors (44 in the main cohort and 40 in the validation cohort), and molecular biology data on 15 primary tumors (main cohort) were analyzed. INTERVENTION: There was no intervention. MAIN OUTCOME: The main outcome was the specific survival after discovery of the first metastasis (Kaplan-Meier method). This included univariate analysis on the main cohort, confirmed on the validation cohort and then analyzed in a multivariate analysis. RESULTS: In the main cohort, overall median survival was 20 months. In univariate analysis, the presence of hepatic and bone metastases, the number of metastatic lesions and the number of tumoral organs at the time of the first metastasis, a high mitotic rate (>20 per 50 high-power field), and atypical mitoses in the primary tumor predicted survival (P = 0.05, 0.003, 0.046, 0.001, 0.01, and < 0.001, respectively). The number of tumoral organs and a high mitotic rate were confirmed on the validation cohort (P = 0.009 and 0.03, respectively). These two parameters were confirmed in multivariate analysis (P = 0.0058 and 0.049). CONCLUSION: Metastatic ACC is a heterogeneous disease with poor outcome. The combination of the number of tumoral organs at the time of the first metastasis and the mitotic rate can predict different outcomes.

Integrity signals

Registry

Crossref · 10.1210/jc.2006-0706

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors
Weiss, L. M. (1984) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198403000-00001 · Cited by 920 · cited 2×
“Atypical mitoses have also been considered as a significant diagnostic parameter in a one-score pathological system (37), associated with a low disease-free survival in a univariate analysis in another study (12), and identified as an important predictor of malignancy in childhood adrenocortical tumors (41).”
BackgroundMethod
Pathologic features of prognostic significance in adrenocortical carcinoma
Weiss, L. M., Medeiros, L. J., & Vickery, A. L. (1989) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198903000-00004 · Cited by 818 · cited 2×
“From a prognostic point of view, the mitotic index or the Ki-67 staining index has emerged as single parameters correlated with survival in various studies (11, 12, 17, 19, 39, 40).”
BackgroundMethod
Adrenocortical Carcinoma: Clinical Update
Allolio, B., & Fassnacht, M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2639 · Cited by 775
Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy
Luton, J.-P., Cerdas, S., Billaud, L., Thomas, G., Guilhaume, B., Bertagna, X., Laudat, M.-H., Louvel, A., Chapuis, Y., Blondeau, P., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199004263221705 · Cited by 717
Self-citation
Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group
Icard, P., Goudet, P., Charpenay, C., Andreassian, B., Carnaille, B., Chapuis, Y., Cougard, P., Henry, J., & Proye, C. (2001) · World Journal of Surgery · doi:10.1007/s00268-001-0047-y · Cited by 543

Show all 54 references

Sorted by citations

European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors
Faßnacht, M., Dekkers, O. M., Else, T., Baudin, É., Berruti, A., de Krijger, R. R., Haak, H. R., Mihai, R., Assié, G., & Terzolo, M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0608 · Cited by 976
Adrenocortical carcinoma
Else, T., Kim, A. C., Sabolch, A., Raymond, V. M., Kandathil, A., Caoili, E. M., Jolly, S., Miller, B. S., Giordano, T. J., & Hammer, G. D. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1029 · Cited by 892
Combination Chemotherapy in Advanced Adrenocortical Carcinoma
Faßnacht, M., Terzolo, M., Allolio, B., Baudin, É., Haak, H. R., Berruti, A., Welin, S., Schade‐Brittinger, C., Lacroix, A., Jarząb, B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200966 · Cited by 874
Self-citation
Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: Proposal for a Revised TNM Classification
Fassnacht, M., Johanssen, S., Quinkler, M., Bucsky, P., Willenberg, H. S., Beuschlein, F., Terzolo, M., Mueller, H., Hahner, S., Allolio, B., et al. (2009) · Cancer · doi:10.1002/cncr.24030 · Cited by 695
Update in Adrenocortical Carcinoma
Faßnacht, M., Kroiß, M., & Allolio, B. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3020 · Cited by 414
Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling
Giordano, T. J., Kuick, R., Else, T., Gauger, P. G., Vinco, M., Bauersfeld, J., Sanders, D., Thomas, D. G., Doherty, G., & Hammer, G. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1067 · Cited by 401
Adrenocortical carcinoma: a clinician’s update
Fassnacht, M., Libé, R., Kroiss, M., & Allolio, B. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.235 · Cited by 396
Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival
de Reyniès, A., Assié, G., Rickman, D. S., Tissier, F., Groussin, L., René-Corail, F., Dousset, B., Bertagna, X., Clauser, E., & Bertherat, J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.5678 · Cited by 382
Self-citation
Clinical management of adrenocortical carcinoma
Fassnacht, M., & Allolio, B. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.10.008 · Cited by 349
Prognostic factors in stage III–IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study
Libé, R., Borget, I., Ronchi, C. L., Zaggia, B., Kroiß, M., Kerkhofs, T. M. A., Bertherat, J. Y., Volante, M., Quinkler, M. O., Chabre, O., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv329 · Cited by 267
Self-citation
High Diagnostic and Prognostic Value of Steroidogenic Factor-1 Expression in Adrenal Tumors
Sbiera, S., Schmull, S., Assié, G., Voelker, H.-U., Kraus, L., Beyer, M., Ragazzon, B., Beuschlein, F., Willenberg, H. S., Hahner, S., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0653 · Cited by 241
Self-citation
Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment
Libé, R. (2015) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2015.00045 · Cited by 233
European Society of Endocrine Surgeons (ESES) and European Network for the Study of Adrenal Tumours (ENSAT) recommendations for the surgical management of adrenocortical carcinoma
Gaujoux, S., Mihai, R., Carnaille, B. M. L., Dousset, B. E., Fiori, C., Porpiglia, F., Hellman, P., Iacobone, M., Kraimps, J. L., Donatini, G., et al. (2017) · British journal of surgery · doi:10.1002/bjs.10414 · Cited by 226
The Weiss system for evaluating adrenocortical neoplasms: 25 years later
Lau, S. K., & Weiss, L. M. (2009) · Human Pathology · doi:10.1016/j.humpath.2009.03.010 · Cited by 223
The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: A North American validation
Giovanni Lughezzani, A., Sun, M., Perrotte, P., Claudio Jeldres, A., Alasker, A., Hendrik Isbarn, A., Budäus, L., Shariat, S. F., Guazzoni, G. F., Montorsi, F., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2009.12.007 · Cited by 214
Adjuvant Therapies and Patient and Tumor Characteristics Associated With Survival of Adult Patients With Adrenocortical Carcinoma
Else, T., Williams, A. R., Sabolch, A. N., Jolly, S., Miller, B. S., & Hammer, G. D. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2856 · Cited by 199
Radiotherapy in adrenocortical carcinoma
Polat, B., Fassnacht, M., Pfreundner, L., Guckenberger, M., Bratengeier, K., Johanssen, S., Kenn, W., Hahner, S., Allolio, B., & Flentje, M. (2009) · Cancer · doi:10.1002/cncr.24331 · Cited by 189
Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial
Kroiss, M., Quinkler, M., Johanssen, S., van Erp, N. P., Lankheet, N., Pöllinger, A., Laubner, K., Strasburger, C. J., Hahner, S., Müller, H.-H., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1419 · Cited by 175
Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study
Hermsen, I. G., Fassnacht, M., Terzolo, M., Houterman, S., den Hartigh, J., Leboulleux, S., Daffara, F., Berruti, A., Chadarevian, R., Schlumberger, M., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2676 · Cited by 173
Self-citation
Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial
Tourneau, C. L., Hoimes, C. J., Zarwan, C., Wong, D. J. L., Bauer, S., Claus, R., Wermke, M., Hariharan, S., von Heydebreck, A., Kasturi, V., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0424-9 · Cited by 173
Prognostic Role of Overt Hypercortisolism in Completely Operated Patients with Adrenocortical Cancer
Berruti, A., Faßnacht, M., Haak, H. R., Else, T., Baudin, É., Sperone, P., Kroiß, M., Kerkhofs, T. M. A., Williams, A. R., Ardito, A., et al. (2013) · European Urology · doi:10.1016/j.eururo.2013.11.006 · Cited by 158
Self-citation
Improved Survival in Patients with Stage II Adrenocortical Carcinoma Followed Up Prospectively by Specialized Centers
Faßnacht, M., Johanssen, S., Fenske, W., Weismann, D., Agha, A., Beuschlein, F., Führer, D., Jurowich, C. F., Quinkler, M. O., Petersenn, S., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0803 · Cited by 156
Treatment of Advanced Adrenocortical Carcinoma with Erlotinib plus Gemcitabine
Quinkler, M. O., Hahner, S., Wortmann, S., Johanssen, S., Adam, P., Ritte, C., Strasburger, C. J., Allolio, B., & Faßnacht, M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2564 · Cited by 149
β-Catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma
Gaujoux, S., Grabar, S., Fassnacht, M., Ragazzon, B., Launay, P., Libé, R., Chokri, I., Audebourg, A., Royer, B., Sbiera, S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2006 · Cited by 146
Self-citation
Management of Endocrine Manifestations and the Use of Mitotane As a Chemotherapeutic Agent for Adrenocortical Carcinoma
Veytsman, I. G., Nieman, L. K., & Fojo, T. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.2775 · Cited by 147
Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification
Volante, M., Bollito, E., Sperone, P., Tavaglione, V., Daffara, F., Porpiglia, F., Terzolo, M., Berruti, A., & Papotti, M. G. (2009) · Histopathology · doi:10.1111/j.1365-2559.2009.03423.x · Cited by 138
Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma
Berruti, A., Sperone, P., Ferrero, A., Germano, A., Ardito, A., Priola, A. M., Francia, S. D., Volante, M., Daffara, F., Generali, D., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0918 · Cited by 138
Self-citation
Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma
Megerle, F., Herrmann, W., Schlötelburg, W., Ronchi, C. L., Pulzer, A., Quinkler, M. O., Beuschlein, F., Hahner, S., Kroiß, M., Faßnacht, M., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02591 · Cited by 135
Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis?
Leboulleux, S., Deandreis, D., Al Ghuzlan, A., Aupérin, A., Goéré, D., Dromain, C., Elias, D., Caillou, B., Travagli, J. P., De Baere, T., et al. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-1096 · Cited by 133
Self-citation
Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma
Wortmann, S., Quinkler, M., Ritter, C., Kroiss, M., Johanssen, S., Hahner, S., Allolio, B., & Fassnacht, M. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0804 · Cited by 133
The Weiss Score and Beyond—Histopathology for Adrenocortical Carcinoma
Papotti, M. G., Libé, R., Duregon, E., Volante, M., Bertherat, J. Y., & Tissier, F. (2011) · Hormones and Cancer · doi:10.1007/s12672-011-0088-0 · Cited by 132
Self-citation
Contemporary Management of Adrenocortical Carcinoma
Laurent Zini, A., Porpiglia, F., & Faßnacht, M. (2011) · European Urology · doi:10.1016/j.eururo.2011.07.062 · Cited by 111
Management of adrenal cancer: a 2013 update
Terzolo, M., Daffara, F., Ardito, A., Zaggia, B., Basile, V., Ferrari, L., & Berruti, A. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-013-0049-2 · Cited by 109
Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells
Hescot, S., Slama, A., Lombès, A., Paci, A., Remy, H., Leboulleux, S., Chadarévian, R., Trabado, S., Amazit, L., Young, J., et al. (2013) · Endocrine Related Cancer · doi:10.1530/erc-12-0368 · Cited by 104
Self-citation
S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study
Elhassan, Y. S., Altieri, B., Berhane, S., Cosentini, D., Calabrese, A., Haissaguerre, M., Kaštelan, D., Fragoso, M. C. B. V., Bertherat, J. Y., Ghuzlan, A. A., et al. (2021) · European Journal of Endocrinology · doi:10.1530/eje-21-0510 · Cited by 95
Self-citation
Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study
Fay, A. P., Signoretti, S., Callea, M., Teló, G. H., McKay, R. R., Song, J., Carvo, I., Lampron, M. E., Kaymakcalan, M. D., Poli‐de‐Figueiredo, C. E., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0047-3 · Cited by 94
Urine steroid metabolomics as a novel tool for detection of recurrent adrenocortical carcinoma
Chortis, V., Bancos, I., Nijman, T., Gilligan, L. C., Taylor, A. E., Ronchi, C. L., O’Reilly, M. W., Schreiner, J., Asia, M., Riester, A., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz141 · Cited by 93
Self-citation
Influence of hormonal functional status on survival in adrenocortical carcinoma: systematic review and meta-analysis
Vanbrabant, T., Fassnacht, M., Assie, G., & Dekkers, O. M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0450 · Cited by 91
Value of Molecular Classification for Prognostic Assessment of Adrenocortical Carcinoma
Assié, G., Jouinot, A., Faßnacht, M., Libé, R., Garinet, S., Jacob, L., Hamzaoui, N., Néou, M., Sakat, J., Villéon, B. D. L., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1558 · Cited by 90
Self-citation
[131I]Iodometomidate for targeted radionuclide therapy of advanced adrenocortical carcinoma
Hahner, S., Kreissl, M. C., Fassnacht, M., Haenscheid, H., Knoedler, P., Lang, K., Buck, A. K., Reiners, C., Allolio, B., & Schirbel, A. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2765 · Cited by 87
Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade
Miller, B. S., Gauger, P. G., Hammer, G. D., Giordano, T. J., & Doherty, G. M. (2010) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-010-0698-y · Cited by 84
Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma
Fenske, W., Völker, H., Adam, P., Hahner, S., Johanssen, S., Wortmann, S., Schmidt, M., Morcos, M., Müller–Hermelink, H., Allolio, B., et al. (2009) · Endocrine Related Cancer · doi:10.1677/erc-08-0211 · Cited by 84
Analysis of the Role of Igf2 in Adrenal Tumour Development in Transgenic Mouse Models
Drelon, C., Berthon, A. S., Ragazzon, B., Tissier, F., Bandiera, R., Sahut‐Barnola, I., de Joussineau, C., Batisse‐Lignier, M., Lefrançois‐Martinez, A., Bertherat, J. Y., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044171 · Cited by 81
Self-citation
Pathological and molecular features of adrenocortical carcinoma: an update
Volante, M., Buttigliero, C., Greco, E., Berruti, A., & Papotti, M. G. (2008) · Journal of Clinical Pathology · doi:10.1136/jcp.2007.050625 · Cited by 74
A Modern Assessment of Cancer Risk in Adrenal Incidentalomas
Kahramangil, B., Köse, E., Remer, E. M., REYNOLDS, J. P., Stein, R. J., Rini, B. I., SIPERSTEIN, A. E., & Berber, E. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000004048 · Cited by 73
DNA methylation is an independent prognostic marker of survival in adrenocortical cancer
Jouinot, A., Assié, G., Libé, R., Faßnacht, M., Papathomas, T. G., Barreau, O., Villéon, B. D. L., Faillot, S., Hamzaoui, N., Néou, M., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3205 · Cited by 71
Self-citation
Ribonucleotide Reductase Large Subunit ( RRM1 ) Gene Expression May Predict Efficacy of Adjuvant Mitotane in Adrenocortical Cancer
Volante, M., Terzolo, M., Fassnacht, M., Rapa, I., Germano, A., Sbiera, S., Daffara, F., Sperone, P., Scagliotti, G., Allolio, B., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2692 · Cited by 69
Bilateral adrenalectomy in the 21st century: when to use it for hypercortisolism?
Guérin, C., Taïeb, D., Treglia, G., Brue, T. C., Lacroix, A., Sebag, F. A., & Castinetti, F. (2016) · Endocrine Related Cancer · doi:10.1530/erc-15-0541 · Cited by 69
Role of microRNAs in endocrine cancer metastasis
Lima, C. R., Gomes, C. C., & dos Santos, M. F. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.03.015 · Cited by 69
FDG PET in the Management of Patients with Adrenal Masses and Adrenocortical Carcinoma
Deandreis, D., Leboulleux, S., Caramella, C., Schlumberger, M. J., & Baudin, É. (2011) · Hormones and Cancer · doi:10.1007/s12672-011-0091-5 · Cited by 69
Self-citation
Resection of Adrenocortical Carcinoma Liver Metastasis: Is it Justified?
Gaujoux, S., Al‐Ahmadie, H. A., Allen, P. J., Gönen, M., Shia, J., D'Angelica, M. I., DeMatteo, R. P., Fong, Y., Blumgart, L. H., & Jarnagin, W. R. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2358-7 · Cited by 68
High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up
Mauclère-Denost, S., Leboulleux, S., Borget, I., Paci, A., Young, J., Ghuzlan, A. A., Deandreis, D., Drouard, L., Tabarin, A., Chanson, P., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0557 · Cited by 66
Self-citation
Adrenocortical Carcinoma
Baudin, É. (2015) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2015.03.001 · Cited by 66
Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy
Ronchi, C. L., Sbiera, S., Kraus, L., Wortmann, S., Johanssen, S., Adam, P., Willenberg, H. S., Hahner, S., Allolio, B., & Faßnacht, M. (2009) · Endocrine Related Cancer · doi:10.1677/erc-08-0224 · Cited by 64
Objective Response and Prolonged Disease Control of Advanced Adrenocortical Carcinoma with Cabozantinib
Kroiß, M., Megerle, F., Kurlbaum, M., Zimmermann, S., Wendler, J., Jiménez, C., Lapa, C., Quinkler, M. O., Scherf‐Clavel, O., Habra, M. A., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz318 · Cited by 64
Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma
Malandrino, P., Ghuzlan, A. A., Castaing, M., Young, J., Caillou, B., Travagli, J., Elias, D. M., de Baère, T., Dromain, C., Paci, A., et al. (2010) · Endocrine Related Cancer · doi:10.1677/erc-09-0341 · Cited by 60
Self-citation
Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE)
Stigliano, A., Chiodini, I., Giordano, R., Faggiano, A., Canu, L., Casa, S. D., Loli, P., Luconi, M., Mantero, F., & Terzolo, M. (2015) · Journal of Endocrinological Investigation · doi:10.1007/s40618-015-0349-9 · Cited by 61
Transcatheter Arterial Chemoembolization for Liver Metastases in Patients with Adrenocortical Carcinoma
Cazejust, J., de Baère, T., Auperin, A., Deschamps, F., Hechelhammer, L., Abdel-Rehim, M., Schlumberger, M. J., Leboulleux, S., & Baudin, É. (2010) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2010.05.020 · Cited by 61
Self-citation
MANAGEMENT OF ENDOCRINE DISEASE: Adrenocortical carcinoma: differentiating the good from the poor prognosis tumors
Jouinot, A., & Bertherat, J. Y. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0027 · Cited by 61
Self-citation
Deficits in the Management of Patients With Adrenocortical Carcinoma in Germany
Johanssen, S., Hahner, S., Saeger, W., Quinkler, M. O., Beuschlein, F., Dralle, H., Haaf, M., Kroiß, M., Jurowich, C. F., Langer, P., et al. (2010) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2010.0885 · Cited by 60
Diagnosis, treatment and outcome of adrenocortical cancer
Mihai, R. (2015) · British journal of surgery · doi:10.1002/bjs.9743 · Cited by 56
Adrenocortical Tumors
Tissier, F., Aubert, S., Leteurtre, E., Ghuzlan, A. A., Patey, M., Decaussin‐Petrucci, M., Doucet, L., Gobet, F., Hoang, C., Mazerolles, C., et al. (2012) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31825a6308 · Cited by 55
Self-citation
Adrenocortical carcinoma: presentation and outcome of a contemporary patient series
Kostiainen, I., Hakaste, L., Kejo, P., Parviainen, H., Laine, T., Löyttyniemi, E., Pennanen, M., Arola, J. T., Haglund, C. H., Heiskanen, I., et al. (2019) · Endocrine · doi:10.1007/s12020-019-01918-9 · Cited by 53
The 'omics' of adrenocortical tumours for personalized medicine
Assié, G., Jouinot, A., & Bertherat, J. Y. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.272 · Cited by 52
Self-citation
Advanced Adrenocortical Carcinoma – What to do when First-Line Therapy Fails?
Megerle, F., Kroiß, M., Hahner, S., & Faßnacht, M. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0715-1946 · Cited by 51
Adrenocortical Carcinoma with Hypercortisolism
Puglisi, S., Perotti, P., Pia, A. R., Reimondo, G., & Terzolo, M. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2018.02.003 · Cited by 50
Diagnostic and prognostic features in adrenocortical carcinoma: a single institution case series and review of the literature
Wanis, K. N., & Kanthan, R. (2015) · World Journal of Surgical Oncology · doi:10.1186/s12957-015-0527-4 · Cited by 49
Clinical and Pathophysiological Implications of Chromosomal Alterations in Adrenocortical Tumors: An Integrated Genomic Approach
Barreau, O., de Reyniès, A., Wilmot-Roussel, H., Guillaud-Bataille, M., Auzan, C., René-Corail, F., Tissier, F., Dousset, B. E., BERTAGNA, X. Y., Bertherat, J. Y., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1588 · Cited by 49
Self-citation
A Diagnostic Approach to Adrenocortical Tumors
Hodgson, A., Pakbaz, S., & Mete, Ö. (2019) · Surgical pathology clinics · doi:10.1016/j.path.2019.08.005 · Cited by 48
Adrenocortical carcinoma and pregnancy: clinical and biological features and prognosis
Abiven, G., Coste, J., Tissier, F., Groussin, L., BILLAUD, L., Dousset, B. E., Goffinet, F., BERTAGNA, X. Y., Bertherat, J. Y., & Raffin‐Sanson, M. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0412 · Cited by 46
Self-citation
Clinicopathological description of 43 oncocytic adrenocortical tumors: importance of Ki-67 in histoprognostic evaluation
Renaudin, K., Smati, S., Wargny, M., Ghuzlan, A. A., Aubert, S., Leteurtre, E., Patey, M., Sibony, M., Stürm, N., Tissier, F., et al. (2018) · Modern Pathology · doi:10.1038/s41379-018-0077-8 · Cited by 44
Self-citation
Adrenocortical carcinoma: Diagnosis, prognostic classification and treatment of localized and advanced disease
Libé, R., & Huillard, O. (2023) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2023.100759 · Cited by 55
Expression of the zinc-finger transcription factor Snail in adrenocortical carcinoma is associated with decreased survival
Waldmann, J., Feldmann, G., Slater, E. P., Langer, P., Buchholz, M., Ramaswamy, A., Saeger, W., Rothmund, Μ., & Fendrich, V. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604755 · Cited by 43
Therapeutic Management of Advanced Adrenocortical Carcinoma: What Do We Know in 2011?
Baudin, É., Leboulleux, S., Ghuzlan, A. A., Chougnet, C., Young, J., Deandreis, D., Dumont, F., Dechamps, F., Caramella, C., Chanson, P., et al. (2011) · Hormones and Cancer · doi:10.1007/s12672-011-0094-2 · Cited by 42
Self-citation
Developing treatment for adrenocortical carcinoma
Kerkhofs, T. M. A., Ettaieb, M. H. T., Hermsen, I. G. C., & Haak, H. R. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0318 · Cited by 41
Gene expression profiling in adrenocortical neoplasia
Assié, G., Giordano, T. J., & Bertherat, J. Y. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.09.044 · Cited by 41
Self-citation
Extremely long survival in six patients despite recurrent and metastatic adrenal carcinoma.
Hermsen, I. G. C., Gelderblom, H. A. J., Kievit, J., Romijn, J. A., & Haak, H. R. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0723 · Cited by 40
Metastatic Adrenocortical Carcinoma: Results of 56 Pulmonary Metastasectomies in 24 Patients
den Winkel, J. O., Pfannschmidt, J., Muley, T., Grünewald, C., Dienemann, H., Faßnacht, M., & Allolio, B. (2011) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2011.07.088 · Cited by 40
Adrenal incidentalomas: Risk of adrenocortical carcinoma and clinical outcomes
O’Neill, C. J., Spence, A., Logan, B., Suliburk, J. W., Soon, P. S. H., Learoyd, D., Sidhu, S. B., & Sywak, M. S. (2010) · Journal of Surgical Oncology · doi:10.1002/jso.21553 · Cited by 40
Surgical management of adrenocortical tumours
Miller, B. S., & Doherty, G. M. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.26 · Cited by 38
Surgical treatment of adrenal carcinoma
Gaujoux, S., Weinandt, M., Bonnet, S., Reslinger, V., Bertherat, J. Y., & Dousset, B. E. (2017) · Journal of Visceral Surgery · doi:10.1016/j.jviscsurg.2017.06.010 · Cited by 38
Self-citation
Adrenocortical cancer: mortality, hormone secretion, proliferation and urine steroids – experience from a single centre spanning three decades
Calissendorff, J., Calissendorff, F. S., & Falhammar, H. (2016) · BMC Endocrine Disorders · doi:10.1186/s12902-016-0095-9 · Cited by 37
Whole-Sellar Stereotactic Radiosurgery for Functioning Pituitary Adenomas
Lee, C., Chen, C., Yen, C.-P., Xu, Z., Schlesinger, D. J., Fezeu, F., & Sheehan, J. P. (2014) · Neurosurgery · doi:10.1227/neu.0000000000000425 · Cited by 35
Expression of FSCN1 and FOXM1 are associated with poor prognosis of adrenocortical carcinoma patients
Liang, J., Liu, Z., Wei, X., Zhou, L., Tang, Y., Zhou, C., Wu, K., Zhang, F., Zhang, F., Lu, Y., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6389-3 · Cited by 35
Practical Considerations in the Evaluation and Management of Adrenocortical Cancer
Balasubramaniam, S., & Fojo, T. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.10.011 · Cited by 34
Identification of Mutations in Cell-Free Circulating Tumor DNA in Adrenocortical Carcinoma: A Case Series
Creemers, S. G., Korpershoek, E., Atmodimedjo, P. N., Dinjens, W. N. M., van Koetsveld, P. M., Feelders, R. A., & Hofland, L. J. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00174 · Cited by 33
Medical suppression of hypercortisolemia in Cushing’s syndrome with particular consideration of etomidate
Heyn, J., Geiger, C., Hinske, L. C., Briegel, J., & Weis, F. C. (2011) · Pituitary · doi:10.1007/s11102-011-0314-3 · Cited by 32
Fluorodesoxyglucose uptake in the remaining adrenal glands during the follow-up of patients with adrenocortical carcinoma: do not consider it as malignancy
Leboulleux, S., Deandreis, D., Escourrou, C., Ghuzlan, A. A., Bidault, F., Auperin, A., Travagli, J. P., Lumbroso, J., Schlumberger, M. J., & Baudin, É. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0666 · Cited by 31
Self-citation
Identification of important invasion and proliferation related genes in adrenocortical carcinoma
Alshabi, A. M., Vastrad, B. M., Shaikh, I. A., & Vastrad, C. M. (2019) · Medical Oncology · doi:10.1007/s12032-019-1296-7 · Cited by 31
Aktuelle TNM-Klassifikationssysteme für das Nebennierenkarzinom
Faßnacht, M., Wittekind, C., & Allolio, B. (2010) · Der Pathologe · doi:10.1007/s00292-010-1306-1 · Cited by 29
Medical Approaches in Adrenocortical Carcinoma
Paragliola, R. M., Corsello, A., Locantore, P., Papi, G., Pontecorvi, A., & Corsello, S. M. (2020) · Biomedicines · doi:10.3390/biomedicines8120551 · Cited by 29
Surgery for recurrent adrenocortical carcinoma: A multicenter retrospective study
Simon, G., Pattou, F. N., Mirallié, É., Lifante, J. C., Nominé-Criqui, C., Arnault, V., de Calan, L., Caillard, C., Carnaille, B. M. L., Brunaud, L., et al. (2016) · Surgery · doi:10.1016/j.surg.2016.08.058 · Cited by 28
Pathological and Genetic Stratification for Management of Adrenocortical Carcinoma
Clay, M. R., Pinto, E. M., Fishbein, L. M., Else, T., & Kiseljak‐Vassiliades, K. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab866 · Cited by 24
Current and Emerging Therapeutic Options in Adrenocortical Cancer Treatment
Stigliano, A., Cerquetti, L., Sampaoli, C., Bucci, B., & Toscano, V. (2012) · Journal of Oncology · doi:10.1155/2012/408131 · Cited by 19
The Role of Immunohistochemical Markers for the Diagnosis and Prognosis of Adrenocortical Neoplasms
Angelousi, A. G., Kyriakopoulos, G., Athanasouli, F., Dimitriadi, A., Kassi, E. N., Aggeli, C., Zografos, G., & Kaltsas, G. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11030208 · Cited by 23
First Case Report of a Sporadic Adrenocortical Carcinoma With Gastric Metastasis and a Synchronous Gastrointestinal Stromal Tumor of the Stomach
Kövecsi, A., Jung, I., Bara, T., Bara, T., Azamfirei, L., Kovács, Z., & Gurzu, S. (2015) · Medicine · doi:10.1097/md.0000000000001549 · Cited by 21
Clinical and molecular prognostic factors in adrenocortical carcinoma
Libé, R. (2018) · Minerva Endocrinology · doi:10.23736/s0391-1977.18.02900-0 · Cited by 21
Clinicopathological and Prognostic Characteristics of CD276 (B7-H3) Expression in Adrenocortical Carcinoma
Liang, J., Liu, Z., Pei, T., Xiao, Y., Zhou, L., Tang, Y., Zhou, C., Wu, K., Zhang, F., Zhang, F., et al. (2020) · Disease Markers · doi:10.1155/2020/5354825 · Cited by 20
Prognostic Parameters of Metastatic Adrenocortical Carcinoma
SCHTEINGART, D. E. (2008) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)79172-8 · Cited by 19
Synchronous vs. Metachronous Metastases in Adrenocortical Carcinoma: an Analysis of the Dutch Adrenal Network
Ettaieb, M. H. T., Duker, J. C., Feelders, R. A., Corssmit, E. P. M., van Oordt, C. W. M. D. H., Timmers, H. J. L. M., Kerstens, M. N., Wilmink, J. W., ZELISSEN, P. M. J., Havekes, B., et al. (2016) · Hormones and Cancer · doi:10.1007/s12672-016-0270-5 · Cited by 19

Authors: Assié, G., Antoni, G., Tissier, F., Caillou, B., Abiven, G., Gicquel, C., Leboulleux, S., Travagli, J.-P., Dromain, C., Bertagna, X., Bertherat, J., Schlumberger, M., & Baudin, E.
Affiliations: Service de Médecine Nucléaire et de Cancérologie Endocrinienne (G.As., S.L., J.-P.T., C.D., M.S., E.B.), Institut Gustave-Roussy, Université Paris XI, 94800 Villejuif, France
Institut Gustave Roussy (FR)
Département d’Anatomo-Pathologie (F.T.), Hôpital Cochin, Université Paris V René Descartes, Faculté de Médécine, Site Cochin-Port-Royal, 75014 Paris, France
Hôpital Cochin (FR)
Inserm (FR)
Centre National de la Recherche Scientifique (FR)
Service d’Endocrinologie (G.Ab., X.B., J.B.), Hôpital Cochin, Université Paris V René Descartes, Faculté de Médécine, Site Cochin-Port-Royal, 75014 Paris, France
ORCID: Leboulleux, Sophie
Dromain, Clarisse
Schlumberger, Martin
Venue: The Journal of Clinical Endocrinology & Metabolism
Publisher: The Endocrine Society
Published: 2007-01-01
Volume: 92
Issue: 1
Pages: 148-154
ISSN: 0021-972X (ISSN-L)
1945-7197
DOI: 10.1210/jc.2006-0706
OpenAlex: W2114699004
Cited by: 236
References: 54
Citations by year: 2026: 1 · 2025: 4 · 2024: 13 · 2023: 14 · 2022: 10 · 2021: 18 · 2020: 10 · 2019: 16 · 2018: 13 · 2017: 8 · 2016: 7 · 2015: 14 · 2014: 18 · 2013: 11 · 2012: 11
FWCI: 10.75
Type: journal article
Language: en
Open access: closed
Locations: The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
Keywords: metastatic adrenocortical carcinoma, prognostic factors, survival, mitotic activity, atypical mitoses, liver metastasis, bone metastasis, number of metastatic lesions, clinical features
MeSH terms: Adolescent, Adrenal Cortex Neoplasms, Adult, Aged, Bone Neoplasms, Female, Humans, Liver Neoplasms, Male, Middle Aged, Prognosis, Retrospective Studies, Cohort Studies, Survival Rate, Multivariate Analysis, Loss of Heterozygosity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Prognostic Parameters of Metastatic Adrenocortical Carcinoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks